tk

HSV-TK substrate is an antitumor agent that induces multi-log cytotoxicity in both HSV-TK-expressing and bystander cells.

TK05 is a potent and selective leukotriene C4 synthase (LTC4S) inhibitor with an IC50 of 95 nM.

TK216 is a potent inhibitor of E26 transformation-specific (ETS) with anticancer activity.

Selective blocker of CaV2.1 P/Q-type calcium channels.

Oxythiamine (Hydroxythiamin) is an antivitamin of thiamine and a transketolase (TK) inhibitor. Oxythiamine inhibits cancer cell proliferation and induces cell cycle arrest. Oxythiamine has potential anticancer activity, inhibits non-oxidative synthesis of ribose, and induces apoptosis.

LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).

Carotegrast methyl (AJM300), an orally-active small molecule, can antagonize the α4 integrin receptor. It is a specific and dual α4β1/α4β7 integrin antagonist.

Locustatachykinin II (Lom-TK II), an insect neuropeptide analogous to the vertebrate tachykinin family, serves as a research tool for investigating insect endocrine systems [1].

Urechistachykinin II (Uru-TK II) is an invertebrate rapid kinin-related peptide (TRPs) isolated from carotenoid worms.

Urechistachykinin I (Uru-TK I) is an invertebrate kalinin-related peptide (TRPs) isolated from thylakoid nematodes.

Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.

EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.

EGFR-TK-IN-2 (compound 10b) is an EGFR-TK inhibitor with an IC50 value of 0.16 μM, and it suppresses cell proliferation.

TK-685 is an orally active, selective, allosteric SHP2 inhibitor with an IC₅₀ of 2.1 nM. It targets the SHP2-mediated AKT and ERK signaling pathways to inhibit the proliferation of esophageal cancer cells and induce apoptosis (apoptosis).

TK-684 is a potent and selective allosteric inhibitor of SHP2, with IC50 values of 2.1 nM for SHP2WT and greater than 1000 nM for SHP2PTP. It inhibits cell proliferation and induces apoptosis (apoptosis). Additionally, TK-684 reduces the protein expression of p-AKT and p-ERK.

TK-129 is an orally active, potent inhibitor of KDM5B with an IC50 of 44 nM and is low-toxicity. TK-129 exhibits cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 can be used in cardiovascular disease studies to reduce isoprenaline-induced myocardial remodelling and fibrosis in vivo, as well as to reduce ang II-induced activation of cardiac fibroblasts in vitro [1].

TK-642 is a potent and selective SHP2 inhibitor with oral activity, based on pyrazole and pyrazine structures (IC50 = 2.7 nmol/L). It effectively inhibits the proliferation of esophageal carcinoma cells and induces apoptosis, making it useful for studying esophageal cancer.

Urechistachykinin II acetate (Uru-TK II acetate) is an invertebrate rapid kinin-related peptide (TRPs) isolated from carotenoid worms, shows antimicrobial activities without a hemolytic effect

Urechistachykinin I acetate(149097-03-0 free base) (Uru-TK I acetate) is an invertebrate kalinin-related peptide (TRPs) isolated from thylakoid nematodes.

EGFR-TK-IN-4 (compound 10k) is an effective and selective inhibitor of EGFR-TK, which possesses anti-tumor activity and can induce cellular apoptosis (Apoptosis).

EGFR-TK-IN-3 (3) acts as an inhibitor of EGFR, exhibiting an IC50 value of 2.33 μM in Erlotinib-resistant A549 cells.

TK4b can be used in the research of leukemia cancer and lymphoid-derived diseases. TK4b is a Janus kinase (JAK) inhibitor with the IC50 values of 18.42 nM and 19.40 nM for JAK3 and JAK2, respectively [1].

TK4g is a potent Janus kinase (JAK) inhibitor, demonstrating IC50 values of 12.61 nM and 15.80 nM against JAK2 and JAK3, respectively. It holds promise for research focused on lymphoid-derived diseases and leukemia cancer [1].

BTK-IN-24 is a Bruton's tyrosine kinase (BTK) inhibitor with potential anticancer activity, and it can be used in the study of myeloproliferative disorders.